Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Nasally delivered SARS-CoV-2 vaccines: future promise and challenges.

Shaw RH., (2023), Lancet Respir Med, 11, 1038 - 1039

Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing

Delpuech O. et al, (2022), Scientific Reports, 12

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Liu X. et al, (2021), SSRN Electronic Journal

Transmission dynamics of SARS-CoV-2 in the hospital setting

Mo Y. et al, (2021)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

Dejnirattisai W. et al, (2021)

Improving Robustness of Pharmaceutical Dosage form Sample Preparation Using Experimental Design and Process Understanding Tools

Ferguson PD. et al, (2020), Chromatographia, 83, 1525 - 1538

Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study

Eyre DW. et al, (2020)

Design, analysis and reporting of tumor models

Shaw R. et al, (2017), Lab Animal, 46, 207 - 211

Identification of pharmacodynamic transcript biomarkers in response to FGFR inhibition by AZD4547

Delpuech O. et al, (2016), Molecular Cancer Therapeutics, 15, 2802 - 2813

Overcoming Obstacles in the Implementation of Factorial Design for Assay Optimization

Shaw R. et al, (2015), Assay and Drug Development Technologies, 13, 88 - 93

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib

Pommier AJC. et al, (2014), British Journal of Cancer, 111, 1590 - 1604

Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies

Farren M. et al, (2012), Angiogenesis, 15, 555 - 568

Reduction in laboratory animal use by factorial design

Shaw R., (2004), ATLA Alternatives to Laboratory Animals, 32, 49 - 51

Use of factorial designs to optimize animal experiments and reduce animal use

Shaw R. et al, (2002), ILAR Journal, 43, 223 - 232

Include forthcoming?